Molecular mechanisms of HIV latency.
In J Clin Invest, Feb 2016
These proposed therapies include PKC and MAPK agonists as well as histone deacetylase inhibitors (HDACis) and bromodomain and extraterminal (BET) bromodomain inhibitors (BETis), which act synergistically to reactivate HIV in latently infected cells.
Bromodomains: Structure, function and pharmacology of inhibition.
Los Angeles, United States. In Biochem Pharmacol, Jan 2016
The demonstration in 2010 that two small molecule compounds, JQ1 and I-BET762, potently inhibit proteins of the bromodomain and extra-terminal (BET) family with translational potential for cancer and inflammatory disease sparked intense efforts in academia and pharmaceutical industry to develop novel bromodomain antagonists for therapeutic applications.
BET bromodomain inhibitors in leukemia.
Cambridge, United Kingdom. In Exp Hematol, Aug 2015
The last few years have seen the identification of bromodomain and extraterminal (BET) proteins as critical mediators of transcription with effects on its direct control and cisregulation.
Beating the odds: BETs in disease.
Oxford, United Kingdom. In Trends Biochem Sci, Aug 2015
Recent developments targeting the bromo and extraterminal (BET) subset of BRD proteins demonstrated remarkable efficacy in murine models providing a compelling rationale for drug development and translation to the clinic.